BRPI0911699B8 - vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste - Google Patents

vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste

Info

Publication number
BRPI0911699B8
BRPI0911699B8 BRPI0911699A BRPI0911699A BRPI0911699B8 BR PI0911699 B8 BRPI0911699 B8 BR PI0911699B8 BR PI0911699 A BRPI0911699 A BR PI0911699A BR PI0911699 A BRPI0911699 A BR PI0911699A BR PI0911699 B8 BRPI0911699 B8 BR PI0911699B8
Authority
BR
Brazil
Prior art keywords
antibody
antigen
influenza
antibodies
vector
Prior art date
Application number
BRPI0911699A
Other languages
English (en)
Portuguese (pt)
Inventor
Lanzavecchia Antonio
Original Assignee
Inst Res Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Res Biomedicine filed Critical Inst Res Biomedicine
Publication of BRPI0911699A2 publication Critical patent/BRPI0911699A2/pt
Publication of BRPI0911699B1 publication Critical patent/BRPI0911699B1/pt
Publication of BRPI0911699B8 publication Critical patent/BRPI0911699B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0911699A 2008-07-25 2009-07-27 vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste BRPI0911699B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8383808P 2008-07-25 2008-07-25
US61/083,838 2008-07-25
US18158209P 2009-05-27 2009-05-27
US61/181,582 2009-05-27
PCT/IB2009/006616 WO2010010466A2 (en) 2008-07-25 2009-07-27 Neutralizing anti-influenza a virus antibodies and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0911699A2 BRPI0911699A2 (pt) 2014-09-23
BRPI0911699B1 BRPI0911699B1 (pt) 2020-11-17
BRPI0911699B8 true BRPI0911699B8 (pt) 2023-02-28

Family

ID=41570664

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911699A BRPI0911699B8 (pt) 2008-07-25 2009-07-27 vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste

Country Status (20)

Country Link
US (2) US8685402B2 (OSRAM)
EP (2) EP2313433A2 (OSRAM)
JP (3) JP2011528902A (OSRAM)
KR (2) KR20110049802A (OSRAM)
CN (2) CN102216327A (OSRAM)
AU (2) AU2009275227A1 (OSRAM)
BR (1) BRPI0911699B8 (OSRAM)
CA (2) CA2731686C (OSRAM)
CO (1) CO6341572A2 (OSRAM)
CR (2) CR20110079A (OSRAM)
EC (1) ECSP11010823A (OSRAM)
ES (1) ES2662519T3 (OSRAM)
GT (1) GT201100023A (OSRAM)
IL (2) IL210772A0 (OSRAM)
MA (1) MA32577B1 (OSRAM)
MX (2) MX2011000768A (OSRAM)
NZ (2) NZ590891A (OSRAM)
RU (1) RU2553325C2 (OSRAM)
WO (2) WO2010010466A2 (OSRAM)
ZA (2) ZA201101113B (OSRAM)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010127156A (ru) 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
CN102216327A (zh) * 2008-07-25 2011-10-12 生物医学研究所 中和抗甲型流感病毒抗体及其用途
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
EP2545074A4 (en) * 2010-03-08 2014-01-08 Celltrion Inc HUMAN MONOCLONAL ANTIBODIES MADE FROM HUMAN B-CELLS WITH NEUTRALIZING EFFECT AGAINST INFLUENZA A-VIRUS
ES2687706T3 (es) * 2010-06-17 2018-10-26 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la gripe
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
WO2012145572A1 (en) 2011-04-20 2012-10-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
JP5683752B2 (ja) 2011-07-14 2015-03-11 クルセル ホランド ベー ヴェー 系統グループ１及び系統グループ２のインフルエンザａ型ウイルス、並びにインフルエンザｂ型ウイルスを中和することが可能なヒト結合分子
CN107417789A (zh) * 2011-07-18 2017-12-01 生物医学学会 中和抗甲型流感病毒抗体及其用途
EP3418300B1 (en) * 2011-07-18 2020-10-28 Institute for Research in Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
EP2739312B1 (en) * 2011-08-03 2017-10-04 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
US9512202B2 (en) 2011-08-27 2016-12-06 University Of Zurich Multi-strain-reactive antibodies for therapy and diagnosis of influenza
WO2013048153A2 (ko) * 2011-09-30 2013-04-04 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
WO2013059524A2 (en) * 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
KR20130059721A (ko) * 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
SG11201402780UA (en) 2011-12-02 2014-10-30 Aimm Therapeutics Bv Influenza a virus specific antibodies
JP6371222B2 (ja) * 2011-12-05 2018-08-08 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザの受動免疫用抗体
US20140335507A1 (en) * 2011-12-12 2014-11-13 Novartis Ag Assays for influenza virus hemagglutinins
WO2013089496A1 (ko) * 2011-12-15 2013-06-20 (주)에이프로젠 H1n1-감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
RU2502745C2 (ru) * 2011-12-30 2013-12-27 Общество с ограниченной ответственностью "Технофарма" Наноантитело "anti-flu", рекомбинантные вирусные векторы и фармацевтические композиции для профилактики и терапии гриппа типа а
EA028433B1 (ru) * 2012-03-08 2017-11-30 Янссен Вэксинс Энд Превеншн Б.В. Антитело, связывающееся с вирусами гриппа b и его применение
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CN109265541A (zh) 2012-05-10 2019-01-25 麻省理工学院 流感中和药剂
CN103665156B (zh) * 2012-09-14 2016-08-03 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的结合分子3e1
CN103665157B (zh) * 2012-09-14 2016-06-29 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1c4
CN103665155B (zh) * 2012-09-14 2016-07-06 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1f2
CN103665154B (zh) * 2012-09-14 2016-08-03 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子3c4
SG11201503734UA (en) 2012-11-13 2015-06-29 Genentech Inc Anti-hemagglutinin antibodies and methods of use
EP3003373A4 (en) 2013-03-14 2016-10-19 Contrafect Corp COMPOSITION AND METHODS BASED ON INTRANASALLY RELEASED NEUTRALIZING ANTIBODIES FOR IMPROVED THERAPEUTIC EFFECTIVENESS
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN104098692B (zh) * 2013-04-02 2018-11-30 厦门大学 识别流感病毒血凝素蛋白ha1结构域的广谱单克隆抗体
SG10202103140XA (en) * 2013-10-02 2021-05-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
JPWO2015068781A1 (ja) * 2013-11-06 2017-03-09 国立大学法人大阪大学 インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
RU2720282C1 (ru) 2014-02-04 2020-04-28 Контрафект Корпорейшн Антитела, подходящие для пассивной иммунизации против гриппа, и их композиции, комбинации и способы применения
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CN104892753B (zh) * 2014-03-07 2019-11-29 神州细胞工程有限公司 一种中和人感染h7n9甲型流感病毒的抗体及其用途
SG11201609207SA (en) 2014-05-13 2016-12-29 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
JP6495434B2 (ja) * 2014-07-14 2019-04-03 ザ ペン ステイト リサーチ ファンデーション サーファクタントタンパク質ａ受容体を標的とする組成物及び方法
RU2739952C2 (ru) 2014-07-15 2020-12-30 МЕДИММЬЮН, ЭлЭлСи Нейтрализующие антитела к вирусу гриппа b и пути их применения
WO2016010160A1 (ja) * 2014-07-18 2016-01-21 国立感染症研究所長が代表する日本国 抗インフルエンザウイルス抗体及びその利用
WO2016089181A1 (ko) * 2014-12-05 2016-06-09 (주)셀트리온 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물
US20180008702A1 (en) * 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN108135994B (zh) * 2015-05-13 2022-01-25 宾夕法尼亚州大学信托人 Aav-介导的抗-流感抗体的表达及其使用方法
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
WO2017147248A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
ES2968923T3 (es) * 2016-08-10 2024-05-14 Celltrion Inc Preparación farmacéutica líquida estable de anticuerpo contra el virus de la gripe
JP2017086068A (ja) * 2016-10-31 2017-05-25 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
RU2671477C2 (ru) * 2016-12-30 2018-10-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA2m1F16-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA2m1
RU2656142C1 (ru) * 2016-12-30 2018-05-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA1
RU2664184C2 (ru) * 2016-12-30 2018-08-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-Intht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IgA1
SG11201907611WA (en) 2017-02-28 2019-09-27 Univ Pennsylvania Influenza vaccines based on aav vectors
US11827906B2 (en) 2017-02-28 2023-11-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
WO2019055481A1 (en) * 2017-09-18 2019-03-21 Amyris, Inc. METHODS OF GENOMIC INTEGRATION IN PICHIA AND OTHER HOST CELLS
CN111386343A (zh) 2017-09-18 2020-07-07 阿迈瑞斯公司 用于克鲁维酵母宿主细胞基因组整合的方法
CN109988236B (zh) * 2017-12-30 2022-04-01 中国科学院天津工业生物技术研究所 一种流感病毒抗体的应用
US11447526B2 (en) * 2018-01-23 2022-09-20 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
JP6622825B2 (ja) * 2018-01-25 2019-12-18 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
MA51681A (fr) 2018-01-26 2021-05-05 Regeneron Pharma Anticorps humains contre l'hémagglutinine de la grippe
MX2021000951A (es) 2018-07-23 2021-06-23 Sumitomo Pharma Co Ltd Composición que contiene vacuna contra la influenza.
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
EP3936147A4 (en) 2019-03-04 2022-09-28 JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases METHOD FOR PREPARING A SPLIT VACCINE AGAINST INFLUENZA HEMAGGLUTININ (HA)
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
JP2020048568A (ja) * 2019-11-22 2020-04-02 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
EP4073107A1 (en) 2019-12-11 2022-10-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
CN111825763B (zh) * 2020-07-15 2022-04-19 扬州大学 流感病毒ha蛋白茎部特异性单克隆抗体及其制备方法和应用
CN114181303B (zh) * 2020-09-14 2022-12-23 东莞市朋志生物科技有限公司 抗甲型流感病毒的抗体和试剂盒
EP4256065A2 (en) 2020-12-01 2023-10-11 The Trustees of The University of Pennsylvania Novel compositions with tissue-specific targeting motifs and compositions containing same
AU2022264509A1 (en) 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
KR20240161965A (ko) 2022-03-14 2024-11-13 제너레이션 바이오 컴퍼니 이종 프라임 부스트 백신 조성물 및 사용 방법
KR20240088574A (ko) 2022-11-21 2024-06-20 (주)샤페론 인플루엔자 바이러스에 대한 단일 도메인 항체 및 이의 용도
CN119930806B (zh) * 2025-01-21 2025-12-02 中国医学科学院病原生物学研究所 一种甲型流感病毒中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630064A (en) * 1899-02-10 1899-08-01 William Martindale Safety-hook.
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) * 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
RU2031941C1 (ru) * 1991-03-14 1995-03-27 Научно-исследовательский институт гриппа РАМН Штамм вируса гриппа а(нini) для получения живой гриппозной интраназальной вакцины для взрослых и детей
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2229043C (en) * 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
WO1998057993A1 (en) * 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US8101553B1 (en) * 2000-02-22 2012-01-24 Medical & Biological Laboratories Co., Ltd. Antibody library
WO2004007667A2 (en) 2002-07-11 2004-01-22 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
CN1756562A (zh) * 2003-03-07 2006-04-05 麦克公司 流感病毒疫苗
CN103446582A (zh) * 2003-08-11 2013-12-18 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
MY144906A (en) * 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
TWI477602B (zh) * 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
MY170607A (en) * 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008054606A2 (en) 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
JP5346820B2 (ja) 2007-03-13 2013-11-20 エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US8871207B2 (en) * 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CN102216327A (zh) 2008-07-25 2011-10-12 生物医学研究所 中和抗甲型流感病毒抗体及其用途

Also Published As

Publication number Publication date
US20100086555A1 (en) 2010-04-08
NZ590891A (en) 2013-03-28
KR20110049802A (ko) 2011-05-12
ZA201101113B (en) 2012-08-29
CA2733218A1 (en) 2010-01-28
IL210771A0 (en) 2011-03-31
RU2011105062A (ru) 2012-08-27
JP2011528901A (ja) 2011-12-01
WO2010010466A3 (en) 2010-07-29
EP2313112B1 (en) 2017-12-27
JP5607620B2 (ja) 2014-10-15
WO2010010467A2 (en) 2010-01-28
AU2009275226A1 (en) 2010-01-28
CA2731686A1 (en) 2010-01-28
BRPI0911699B1 (pt) 2020-11-17
JP6022515B2 (ja) 2016-11-09
IL210772A0 (en) 2011-03-31
US9340603B2 (en) 2016-05-17
JP2014237714A (ja) 2014-12-18
RU2553325C2 (ru) 2015-06-10
HK1161110A1 (en) 2012-08-24
GT201100023A (es) 2013-12-10
MX2011000767A (es) 2011-09-21
CN102164613A (zh) 2011-08-24
KR101732056B1 (ko) 2017-05-02
EP2313112A2 (en) 2011-04-27
AU2009275226B2 (en) 2015-05-14
CN102164613B (zh) 2014-11-26
KR20110047193A (ko) 2011-05-06
NZ590890A (en) 2013-05-31
EP2313433A2 (en) 2011-04-27
WO2010010466A2 (en) 2010-01-28
CN102216327A (zh) 2011-10-12
ECSP11010823A (es) 2011-08-31
WO2010010467A3 (en) 2010-12-16
US20100080813A1 (en) 2010-04-01
CR20110079A (es) 2011-07-18
CO6341572A2 (es) 2011-11-21
BRPI0911699A2 (pt) 2014-09-23
AU2009275227A1 (en) 2010-01-28
ES2662519T3 (es) 2018-04-06
CR20110084A (es) 2011-07-18
ZA201101150B (en) 2012-08-29
MA32577B1 (fr) 2011-08-01
CA2731686C (en) 2020-04-07
US8685402B2 (en) 2014-04-01
JP2011528902A (ja) 2011-12-01
MX2011000768A (es) 2011-10-05

Similar Documents

Publication Publication Date Title
BRPI0911699B8 (pt) vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
BR112014030797A2 (pt) epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
BR112019005726A8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno
MX2014000749A (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
BRPI1012321A8 (pt) Anticorpos anti-vegf e seus usos
Job et al. Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs
BR112015023262A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BRPI0806185A2 (pt) anticorpo neutralizador de alta potência, fragmento de um anticorpo, molécula de ácido nucléico, vetor, célula, clone de célula b imortalizado, epìtopo, polipeptìdio imunogênico, método para produção de anticorpos, composição farmacêutica, uso de um primeiro anticorpo ou fragmento, composição ou uso, método para tratamento de um sujeito, kit para diagnóstico de infecção por hcmv, método para preparação de uma célula recombinante, método para produção de anticorpos, método de detecção de polipeptìdios e epìtopo que se liga especificamente a um anticorpo
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
BRPI1008692B8 (pt) anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
BRPI0815370B8 (pt) anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
BRPI1009576B8 (pt) anticorpo antagonístico que se liga a il-13 humana e uso deste, molécula de anticorpo neutralizadora, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de anticorpo, composição famacêutica, e uso de fragmento fab ou fab` de anticorpo anti-il 13.
BR112014031689A2 (pt) anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles
MX2024010988A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
EA201891410A1 (ru) Антитела к с5 и способы их применения
BR112018075688A2 (pt) anticorpos anti-c5 e métodos de uso
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
BR112016015678A2 (pt) Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso
BR112017010298A2 (pt) anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus e usos dos mesmos
Gong et al. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B
Deng et al. Tetrameric neuraminidase of influenza A virus is required to induce protective antibody responses in mice
Yuan et al. Preparation and diagnostic use of a novel recombinant single-chain antibody against rabies virus glycoprotein
Xia et al. Generation and application of two monoclonal antibodies targeting conserved linear epitopes in the NP protein of influenza A virus
Stadlbauer et al. Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses?

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: COM BASE NA RESOLUCAO 228/09, SOLICITA-SE QUE SEJAM APRESENTADOS NOVOS CD'S/DVD'S, POIS OS QUE FORAM APRESENTADOS ESTAO VAZIOS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2602 DE 17/11/2020 QUANTO AO QUADRO REIVINDICATORIO.